Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ve... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of P... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Co... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared ... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemother... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose S... Read More
Singapore, Sept. 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating... Read More